Here’s how the FDA’s review of epilepsy drug could affect CBD companies

MJBizDaily
By Kevin HuhnApr 18, 2018, 11:00 pm12 pts
It’s shaping up to be a watershed summer for the cannabis industry with the U.S. Food and Drug Administration poised to approve the first drug made from the plant. The agency's impending decision on Epidiolex, an epilepsy treatment made of CBD extracted from cannabis flower, could upend decades of government…

Read Article Share
Share Article
- email
- twitter
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

California: Lawmakers Advance Legislation to Governor’s Desk Halting Tax Hike on Commercially Available Cannabis Products 78

The Clock Is Ticking on Cannabis Rescheduling 74

PEI’s Retro Cannabis: from micro producer to standard licence 73

California Lawmakers Pass Bill to Undo Cannabis Industry Tax Hike 71

Massachusetts Lawmakers Approve Bill To Create Psychedelic Therapy Pilot Program 71

Another Minnesota Tribe Signs Agreement for Off-Reservation Cannabis Sales 67

Smoking Marijuana With A Water Bong Doesn’t Effectively Filter Compounds From Smoke, Study Suggests 64

NECANN NJ 2025 Cannabis Industry Convention Features New Cup of Champions 64

About NewsBudz

NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates.

Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.

Whether you're interested in policy reform, health research, cannabis business, CBD, delta 9 products or lifestyle stories, NewsBudz keeps you informed and connected. Accessible on the web and mobile, NewsBudz makes it easy to explore, read, and share cannabis news anytime, anywhere.